http://formularyjournal.modernmedicine.com/formulary Formulary provides peer-reviewed clinical information and news and drug approval updates to assist pharmacy and therapeutics committee members with their drug management responsibilities. 2008-10-11T12:21:32Z http://formularyjournal.modernmedicine.com/formulary/Medication+Safety/Case-of-PML-reported-in-efalizumab-treated-patient/ArticleStandard/Article/detail/558053?ref=25 Genentech informed healthcare professionals that a 70-year-old patient who has been treated with efalizumab (Raptiva) for chronic psoriasis for >4 years has developed progressive multifocal leukoencephalopathy (PML), a rare, progressive disease of the central nervous system that is usually fatal. 2008-10-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/558053null HTML http://formularyjournal.modernmedicine.com/formulary/Policy+News/FDA-posts-quarterly-drug-safety-report/ArticleStandard/Article/detail/558055?ref=25 FDA announced that the agency has posted on its website a report listing drugs that are being investigated for potential safety concerns. 2008-10-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/558055null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Tiotropium-improves-long-term-lung-function-in-COP/ArticleStandard/Article/detail/558052?ref=25 In the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, tiotropium therapy for patients with chronic obstructive pulmonary disease (COPD) was associated with long-term improvements in lung function, quality of life, and COPD exacerbations. The therapy did not, however, significantly reduce the rate of decline in forced expiratory volume in 1 second (FEV1) compared with placebo. 2008-10-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/558052null HTML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/Development-of-taranabant-for-obesity-discontinued/ArticleStandard/Article/detail/558056?ref=25 Merck has announced that they are discontinuing development of taranabant, an investigational selective blocker of the cannabinoid-1 (CB-1) receptor that was being studied for the treatment of obesity. 2008-10-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/558056null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Tibolone-reduces-fracture-and-breast-CA-risk-incre/ArticleStandard/Article/detail/558059?ref=25 The Long-Term Intervention on Fractures with Tibolone (LIFT) study demonstrated a reduced risk of vertebral fracture, breast cancer, and possibly colon cancer but a significantly increased risk of stroke in older postmenopausal women treated with tibolone versus those treated with placebo. 2008-10-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/558059null HTML http://formularyjournal.modernmedicine.com/formulary/Cardiovascular/ARBs-demonstrate-no-beneficial-effect-on-mortality/ArticleStandard/Article/detail/556507?ref=25 A systematic search of the literature published in the International Journal of Clinical Practice demonstrated that angiotensin receptor blockers (ARBs) used as monotherapy or in combination with angiotensin-converting enzyme (ACE) inhibitors are not associated with a beneficial effect on mortality in patients with heart failure (HF). 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556507null XML http://formularyjournal.modernmedicine.com/formulary/Neurology/Tetrabenazine-Xenazine-Monoamine-depleter-approved/ArticleStandard/Article/detail/556499?ref=25 New molecular entity: Tetrabenazine (Xenazine), a monoamine depleter, was approved on August 15, 2008, for the treatment of chorea associated with Huntington's disease. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556499null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-October-2008-vernakalant-dori/ArticleStandard/Article/detail/556502?ref=25 Recent FDA action (through October 2008) related to vernakalant, doripenem, custirsen, droxidopa, amrubicin, dronedarone, and imatinib. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556502null XML http://formularyjournal.modernmedicine.com/formulary/Hematology/Eltrombopag-A-TPO-receptor-agonist-for-the-treatme/ArticleStandard/Article/detail/556503?ref=25 Eltrombopag is a TPO receptor agonist that is currently pending FDA approval for the treatment of ITP. This agent has been granted orphan drug and priority review status. In May 2008, the Oncology Drugs Advisory Committee unanimously agreed that eltrombopag demonstrates a favorable risk:benefit profile for the short-term treatment of chronic ITP. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556503null XML http://formularyjournal.modernmedicine.com/formulary/Medication+Safety/Labeling-updates-and-warnings-through-October-2008/ArticleStandard/Article/detail/556506?ref=25 Labeling updates and warnings through October 2008 for adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), infliximab (Remicade), and rituximab (Rituxan). 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556506null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Congress-to-consider-changes-to-Medicare-Part-D-dr/ArticleStandard/Article/detail/556508?ref=25 Even though the Medicare prescription drug benefit has provided access to medications at less-than-anticipated cost to the government—and lower out-of-pocket spending for seniors—many Democrats and consumer advocates want to overhaul the program. Critics contend that the federal government can negotiate prices with pharmaceutical companies that are lower than those obtained by private insurers operating prescription drug plans (PDPs), and some reformers charge that the program is too complex and confusing for elderly beneficiaries, pointing particularly to the infamous "donut hole" that is affecting more Medicare patients than anticipated. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556508null XML http://formularyjournal.modernmedicine.com/formulary/Hematology/Romiplostim-Nplate-Thrombopoietin-mimetic-peptibod/ArticleStandard/Article/detail/556500?ref=25 New biologic: Romiplostim (Nplate), a thrombopoietin mimetic peptibody, was approved on August 22, 2008, for the treatment of chronic ITP. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556500null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-October-2008-Cancidas-Aloxi-V/ArticleStandard/Article/detail/556501?ref=25 Recent FDA approvals and indications (through October 2008) related to Cancidas, Aloxi, and Vidaza. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556501null XML http://formularyjournal.modernmedicine.com/formulary/Respiratory/Ipratropium-associated-with-increased-risk-of-deat/ArticleStandard/Article/detail/556505?ref=25 A nested case-control analysis published in the Annals of Internal Medicine demonstrated an increased risk of all-cause and cardiovascular mortality among patients with recently diagnosed chronic obstructive pulmonary disease (COPD) treated with ipratropium. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556505null XML http://formularyjournal.modernmedicine.com/formulary/Information+for+Authors/License-Agreement-PDF/ArticleStandard/Article/detail/557321?ref=25 Completion of this licensing agreement transferring copyright ownership to Formulary, is required and has to be signed by all article coauthors (a separate form for each author/coauthor of a single manuscript, each showing an original signature is required). The copyright form must not include any written notations other than the original written and printed signature of the author and date. This form should be mailed [not emailed or faxed] to Formulary when the article is submitted for publication consideration. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/557321null PDF http://formularyjournal.modernmedicine.com/formulary/Cardiovascular/Rational-approaches-to-the-treatment-of-mixed-dysl/ArticleStandard/Article/detail/556504?ref=25 This article reviews the role of individual therapeutic agents and combination therapies that can be used for the treatment of mixed dyslipidemia. 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556504/OctoberLipidsArt_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/556689?ref=25 Drug Watch: Agents in late-stage development for the treatment of hepatitis B and C virus infections (October 2008) 2008-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/412008/556689null PDF http://formularyjournal.modernmedicine.com/formulary/Endocrinology/Alogliptin-A-dipeptidyl-peptidase-IV-inhibitor-for/ArticleStandard/Article/detail/546997?ref=25 Alogliptin is a highly selective DPP-IV inhibitor under investigation for the treatment of type 2 diabetes. An NDA for alogliptin was submitted in January 2008, and a response from FDA is expected in the fourth quarter of this year. 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/546997null XML http://formularyjournal.modernmedicine.com/formulary/Prostate+Cancer/Primary-androgen-deprivation-therapy-does-not-prol/ArticleStandard/Article/detail/547001?ref=25 Primary androgen deprivation therapy (PADT), the second most common treatment for localized prostate cancer following prostatectomy, is no more effective than conservative medical management for prolonging survival in most older patients with prostate cancer. 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/547001null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/546160?ref=25 Drug Watch: Agents in late-stage development for the treatment of types 1 and 2 diabetes mellitus (September 2008) 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/352008/546160null PDF http://formularyjournal.modernmedicine.com/formulary/Medication+Safety/Labeling-updates-and-warnings-through-September-20/ArticleStandard/Article/detail/547000?ref=25 Labeling updates and warnings through September 2008 for intramuscular naltrexone (Vivitrol) amd for simvastatin (Zocor; generic simvastatin), ezetimibe/simvastatin (Vytorin), and niacin extended-release/simvastatin (Simcor) when used concurrently with amiodarone (Cordarone; Pacerone; generic amiodarone) 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/547000null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-September-2008/ArticleStandard/Article/detail/546995?ref=25 Recent FDA action (through September 2008) related to Immediate-release diclofenac capsules, tocilizumab, sugammadex, topical alprostadil cream, fospropofol, iloperidone, lacosamide, and vascular endothelial growth factor b. 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/546995null XML http://formularyjournal.modernmedicine.com/formulary/Neurology/Rofecoxib-valdecoxib-associated-with-increased-ris/ArticleStandard/Article/detail/546999?ref=25 A retrospective cohort study published in the journal Stroke demonstrated an increased risk of stroke among users of rofecoxib and valdecoxib but not among users of other nonsteroidal anti-inflammatory drugs (NSAIDs). 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/546999null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-September-2008/ArticleStandard/Article/detail/546994?ref=25 Recent FDA approvals and indications (through September 2008) related to Diovan HCT, Exforge, Cleviprex, Eovist, Stavzor, Promus Everolimus-Eluting stent, and Xience V Everolimus-Eluting stent 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/546994null XML http://formularyjournal.modernmedicine.com/formulary/Feature+Articles/Potentially-inappropriate-medication-use-in-hospit/ArticleStandard/Article/detail/546998?ref=25 The purpose of this drug use evaluation was to report potentially inappropriate medication use, as defined by the full Beers criteria. 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/546998/SeptPIMs_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Comparative-effectiveness-research-legislation-lik/ArticleStandard/Article/detail/547002?ref=25 The Comparative Effectiveness Research Act of 2008 would establish the Health Care Comparative Effectiveness Research Institute as a private, nonprofit, nongovernmental entity that would contract with government agencies and private research organizations to conduct systematic reviews, observational studies, and randomized controlled clinical trials to obtain evidence regarding the clinical effectiveness of therapies and treatments. 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/547002null XML http://formularyjournal.modernmedicine.com/formulary/Complete-access-to-our-September-2008-issue/ArticleStandard/Article/detail/552373?ref=25 Potentially inappropriate medication use in hospitalized older adults: A DUE using the full Beers criteria; Focus on alogliptin; Drug Watch: Agents in late-stage development for the treatment of types 1 and 2 diabetes mellitus 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/392008/552373/PIMsDUEcover_thumbnail.gif http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/392008/552373null REMOTE http://formularyjournal.modernmedicine.com/formulary/Infectious+Disease/Tenofovir-Viread-Antiviral-agent-approved-for-the-/ArticleStandard/Article/detail/546993?ref=25 New indication: Tenofovir (Viread), an antiviral agent, was approved on August 13, 2008, for the treatment of chronic hepatitis B in adults. 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/546993null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/First-time-generic-drug-approvals-September-2008/ArticleStandard/Article/detail/546996?ref=25 Generic drugs approved by FDA (through September 2008) including nisoldipine extended-release tablets and divalproex delayed-release tablets 2008-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362008/546996null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Bortezomib-Velcade-Antineoplastic-agent-approved-f/ArticleStandard/Article/detail/533498?ref=25 New indication: Bortezomib (Velcade), an antineoplastic agent, was approved on June 20, 2008, for the initial treatment of multiple myeloma. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533498null XML http://formularyjournal.modernmedicine.com/formulary/Endocrinology/Addition-of-aliskiren-to-losartan-provides-additio/ArticleStandard/Article/detail/533507?ref=25 A recent multinational, randomized, double-blind, placebo-controlled clinical trial demonstrated that administration of aliskiren provides additional renal protection to patients with hypertension, type 2 diabetes mellitus, and nephropathy who are already receiving optimal antihypertensive therapy and renal protective therapy with the angiotensin receptor blocker (ARB) losartan. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533507null XML http://formularyjournal.modernmedicine.com/formulary/Cardiovascular/Dronedarone-associated-with-increased-mortality-in/ArticleStandard/Article/detail/533503?ref=25 In the Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease (ANDROMEDA) investigators observed that dronedarone, an anti-arrhythmic agent related to amiodarone, was associated with increased mortality in patients who were hospitalized for symptomatic heart failure (HF) (New York Heart Association [NYHA] class II, III, or IV) and left ventricular systolic dysfunction. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533503null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/First-time-generic-drug-approvals-August-2008/ArticleStandard/Article/detail/533500?ref=25 Generic drugs approved by FDA (through August 2008) including risperidone tablets. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533500null XML http://formularyjournal.modernmedicine.com/formulary/Depression/Treatment-with-SSRIs-or-venlaxafine-associated-wit/ArticleStandard/Article/detail/533509?ref=25 In a nested, case-control study published in the Archives of General Psychiatry, investigators observed that the use of selective serotonin-reuptake inhibitors (SSRIs) increased the risk of upper gastrointestinal (GI) tract bleeding; this increased risk was also observed with the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine. This risk may be increased when the agents are used concomitantly with nonsteroidal anti-inflammatory drugs (NSAIDs) and decreased when used concomitantly with acid-suppressing agents. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533509null XML http://formularyjournal.modernmedicine.com/formulary/Feature+Articles/Tocilizumab-A-humanized-anti-IL-6-receptor-monoclo/ArticleStandard/Article/detail/533505?ref=25 Tocilizumab, an investigational agent for the treatment of moderate-to-severe rheumatoid arthritis, is a humanized anti-IL-6 receptor monoclonal antibody. Because tocilizumab contains a mouse monoclonal antibody grafted onto human immunoglobulin, the grafted antibody is less antigenic and has a longer half-life than the mouse antibody. When administered, tocilizumab inhibits IL-6 activity by competing for both the membrane-bound and soluble types of IL-6 receptors, thus eliminating IL-6 transduction into the cell. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533505null XML http://formularyjournal.modernmedicine.com/formulary/Cover+Articles/Clinical-news-updates-from-the-68th-Scientific-Ses/ArticleStandard/Article/detail/533506?ref=25 Among the new data presented at the 68th Scientific Sessions of the ADA were the results of phase 3 trials of the investigational agents liraglutide, ABT-335, saxagliptin, and alogliptin. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533506/ADAAugustFormulary2_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Complete-access-to-our-August-2008-issue/ArticleStandard/Article/detail/542792?ref=25 Clinical updates from the 68th Scientific Sessions of the American Diabetes Association; Focus on tocilizumab; Drug Watch: Agents in late-stage development for the treatment of type 2 diabetes mellitus 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342008/542792/August_Formulary_cover_ADA_thumbnail.gif http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342008/542792null REMOTE http://formularyjournal.modernmedicine.com/formulary/Information+for+Authors/Information-for-Authors-revised-82008-PDF/ArticleStandard/Article/detail/541921?ref=25 Information for Authors (revised 8/2008) (PDF) 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/332008/541921null PDF http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-August-2008/ArticleStandard/Article/detail/533502?ref=25 Recent FDA approvals and indications (through August 2008) related to Concerta, Avodart, Prandimet, Trivaris, Reclast, Requip XL, Aciphex, Aptivus, Kinrix, Pentacel, and Durezol. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533502null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Safety-surveillance-to-transform-drug-development-/ArticleStandard/Article/detail/533511?ref=25 FDA has launched the Sentinel Initiative to expand and improve medical product risk detection and evaluation. Instead of relying on passive, voluntary adverse event (AE) reports sent to FDA by physicians and pharmacists, the agency would be able to detect safety signals much more quickly through links to health information databases containing information about millions of patients. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533511null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-August-2008/ArticleStandard/Article/detail/533499?ref=25 Recent FDA action (through August 2008) related to long-acting depot preparation of testosterone, pancrealipase capsules, human papillomavirus (HPV) quadrivalent (types 6, 11, 16, 18) vaccine, recombinant, tolvaptan, etanercept, ustekinumab, and cysteamine hydrocortisone dual-release table. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533499null XML http://formularyjournal.modernmedicine.com/formulary/Hematology/Erythropoiesis-stimulating-agents-for-anemia-in-ol/ArticleStandard/Article/detail/533641?ref=25 Erythropoietin, a humoral factor produced predominantly in the kidney, stimulates red blood cell production in the bone marrow. Erythropoiesis-stimulating agents (ESAs) have been used for years in the treatment of anemia, with extensive experience and benefits in anemia of chronic kidney disease. Recent data have suggested adverse consequences with use of ESAs, perhaps relating to inappropriate use, and prompting release of guidelines to ensure safe use and maximize benefit. When prescribing ESAs, indications, requirements to monitor laboratory parameters (hemoglobin levels and ferrokinetics), and clinical status need to be stringently followed. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533641null XML http://formularyjournal.modernmedicine.com/formulary/Infectious+Disease/Raltegravir-plus-optimized-background-therapy-supe/ArticleStandard/Article/detail/533510?ref=25 Two randomized, double-blind, phase 3 clinical trials demonstrated that raltegravir plus optimized background therapy was more effective than optimized background therapy alone in suppressing resistant HIV-1. 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533510null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/533279?ref=25 Drug Watch: Agents in late-stage development for the treatment of type 2 diabetes mellitus (August 2008) 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/312008/533279null PDF http://formularyjournal.modernmedicine.com/formulary/Neurology/Duloxetine-Cymbalta-SSNRI-approved-for-the-managem/ArticleStandard/Article/detail/533501?ref=25 New indication: Duloxetine (Cymbalta), an SSNRI, was approved on June 13, 2008, for the management of fibromyalgia 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533501null XML http://formularyjournal.modernmedicine.com/formulary/Medication+Safety/Medication-safety-labeling-updates-and-new-warning/ArticleStandard/Article/detail/533504?ref=25 Labeling updates and warnings through August 2008 for abacavir (Ziagen) and abacavir-containing agents (Epzicom, Trizivir) and ciprofloxacin (Cipro), ciprofloxacin extended-release (Cipro XR. Proquin XR), gemifloxacin (Factive), levofloxacin (Levaquin), moxifloxacin (Avelox), norfloxacin (Noroxin), and ofloxacin (Floxin). 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533504null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Methotrexate-plus-etanercept-effective-in-inducing/ArticleStandard/Article/detail/533508?ref=25 The first phase of a double-blind, randomized, parallel-group, multicenter, outpatient study demonstrated that treatment with the combination of etanercept and methotrexate was more effective in inducing both clinical remission and radiographic nonprogression than methotrexate alone in patients with early moderate-to-severe rheumatoid arthritis (RA). 2008-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322008/533508null XML http://formularyjournal.modernmedicine.com/formulary/CME+Showcase/Reducing-Risk-of-Coronary-Heart-Disease-in-Patient/CME/Article/detail/548974?ref=25 CME Activity 2008-07-16T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/cme/formulary/372008/548974null REMOTE http://formularyjournal.modernmedicine.com/formulary/Policy+News/Orphan-drug-program-continues-to-yield-treatments-/ArticleStandard/Article/detail/527924?ref=25 The US orphan drug program has demonstrated that economic incentives and regulatory flexibility can spur development of treatments for small patient populations. Since enactment of the Orphan Drug Act (ODA) in 1983, FDA has approved >300 medicines for approximately 12 million patients around the world. However, there are approximately 6,000 to 8,000 rare diseases, so “we still have a very long way to go,” commented Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER), at a May conference commemorating ODA’s 25th anniversary, which was sponsored by the Drug Information Association (DIA). 2008-07-03T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527924null HTML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-July-2008/ArticleStandard/Article/detail/527744?ref=25 Recent FDA action (through July 2008) related to tigecycline, bazedoxifene, balsalazide tablet, tacrolimus, fospropofol injection, bivalirudin, 13-valent pneumococcal conjugate vaccine, pirfenidone, LX1032, palifosfamide, SB1518, oral tetrathiomolybdate, and terguride. 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527744null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/Alvimopan-Entereg-Peripherally-acting-mu-opioid-re/ArticleStandard/Article/detail/527741?ref=25 NME: Alvimopan (Entereg), a peripherally acting mu-opioid receptor antagonist, was approved on May 20, 2008, to accelerate the time to upper and lower GI recovery after partial large or small bowel resection surgery with primary anastomosis. 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527741null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/Atomoxetine-Strattera-Selective-norepinephrine-reu/ArticleStandard/Article/detail/527742?ref=25 New indication: Atomoxetine (Strattera), a selective norepinephrine reuptake inhibitor, was approved on May 7, 2008, for the maintenance treatment of ADHD in children and adolescents. 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527742null XML http://formularyjournal.modernmedicine.com/formulary/Cardiovascular/AASK-Aggressive-blood-pressure-control-has-little-/ArticleStandard/Article/detail/527402?ref=25 According to the results of an extended follow-up of the African American Study of Kidney Disease and Hypertension (AASK), long-term reduction of blood pressure to a lower goal than the standard demonstrates no significant effect on the progression of chronic kidney disease (CKD) in nondiabetic hypertensive patients, except in patients with baseline urinary protein/creatinine ratio >0.22, said Jackson Wright, MD, professor of medicine and director of the hypertension program at Case Western Reserve University, Cleveland. These results were presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension, New Orleans, May 14–17, 2008. 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527402null HTML http://formularyjournal.modernmedicine.com/formulary/Cover+Articles/Update-on-the-diagnosis-and-treatment-of-hospital-/ArticleStandard/Article/detail/527747?ref=25 Hospital-acquired pneumonia (HAP) is a frequently occurring complication of endotracheal intubation and hospitalization that is associated with a significant increase in morbidity, mortality, and cost of care. 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527747/JulyHAP_flash.jpg XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Re-Defining-the-Role-of-Pharmacoeconomic-Analyses-/CME/Article/detail/548977?ref=25 CME Activity 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/cme/formulary/372008/548977null REMOTE http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/526907?ref=25 Drugs in development for the treatment of adult and juvenile rheumatoid arthritis 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/526907null PDF http://formularyjournal.modernmedicine.com/formulary/Oncology/Integrating-Recent-Growth-Factor-Evidence-Practice/ArticleStandard/Article/detail/527167?ref=25 Epoetin alfa in 1993 and darbepoetin alfa in 2002 were approved for the management of chemotherapy-induced anemia (CIA). 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527167null PDF http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/First-time-generic-drug-approvals-July-2008/ArticleStandard/Article/detail/527745?ref=25 Generic drugs approved by FDA (through July 2008) including fluoxetine capsules and calcipotriene topical solution. 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527745null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Step-Up-or-Step-Down-How-Are-You-Managing-Your-Inv/CME/Article/detail/548979?ref=25 CME activity 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/cme/formulary/372008/548979null REMOTE http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-July-2008-Abilify-Levaquin-Ta/ArticleStandard/Article/detail/527743?ref=25 Recent FDA approvals and indications (through July 2008) related to Abilify, Levaquin, Taclonex Scalp, Recothrom, and Seroquel. 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527743null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Tolvaptan-A-novel-oral-vasopressin-V2-receptor-ant/ArticleStandard/Article/detail/527746?ref=25 Tolvaptan is an oral selective vasopressin V2 receptor antagonist that works to produce aquaresis (water diuresis without electrolyte excretion) by blocking the effects of AVP. This effect makes tolvaptan a viable treatment option for patients with acute decompensated heart failure (ADHF) and hyponatremia. 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/527746null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Treatment-Strategies-for-Acute-Hypertension/CME/Article/detail/548981?ref=25 CME Activity 2008-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/cme/formulary/372008/548981null REMOTE http://formularyjournal.modernmedicine.com/formulary/Cardiovascular/Amlodipine-plus-olmesartan-superior-to-monotherapy/ArticleStandard/Article/detail/526944?ref=25 The combination of amlodipine and olmesartan was demonstrated to be superior to monotherapy with either agent in difficult-to-treat hypertensive populations in a subgroup analysis of the registrational trial for this combination therapy. These results were presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension, New Orleans, May 14–17, 2008. 2008-06-30T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/526944null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+Pharmacology/Novel-Approaches-to-the-Management-of-Major-Depres/CME/Article/detail/548983?ref=25 CME Activity 2008-06-30T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/cme/formulary/372008/548983null REMOTE http://formularyjournal.modernmedicine.com/formulary/Cardiovascular/Dual-receptor-antagonist-demonstrated-to-be-effect/ArticleStandard/Article/detail/526945?ref=25 An investigational first-in-class dual angiotensin and endothelin receptor antagonist lowered systolic blood pressure (SBP) in patients with stage 1 and 2 hypertension in a phase 2a trial, reported Joel M. Neutel, MD, associate professor of medicine, University of California, Irvine, and medical director of clinical pharmacology, Orange County Research Center, Tustin, California. These results were presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension, New Orleans, May 14–17, 2008. 2008-06-30T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272008/526945null HTML http://formularyjournal.modernmedicine.com/formulary/Coronary-and-aortic-calcium-burden-strongly-predic/ArticleStandard/Article/detail/522700?ref=25 Coronary artery calcium and abdominal aortic calcium both predicted future cardiovascular events in a Veterans Administration population with type 2 diabetes. The relationship between calcium scores and cardiovascular events was independent of standard cardiovascular risk factors, said Peter Reaven, MD. 2008-06-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522700null HTML http://formularyjournal.modernmedicine.com/formulary/Be-wary-of-trace-element-claims/ArticleStandard/Article/detail/522698?ref=25 Clinicians should be wary of health claims made for trace elements such as iron or chromium. While there is no doubt that trace elements are needed for health, there is significant doubt about their utility in preventing or curing diabetes and other diseases, said Eliseo Guallar, MD, DrPH, Johns Hopkins Bloomberg School of Public Health, Baltimore. There are many hypotheses about the beneficial effects of trace elements, but little high-quality data, little reliable population data, few useful biomarkers, relatively crude analytical methods and few mechanistic studies. 2008-06-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522698null HTML http://formularyjournal.modernmedicine.com/formulary/Endovascular-interventions-for-PAD-proliferate/ArticleStandard/Article/detail/522703?ref=25 The range of endothelial interventions for peripheral artery disease (PAD) is proliferating. Today's choices include traditional balloon angioplasty, stents, drug eluting stents and fabric-covered stents. Newer technologies allow clinicians to cut out occlusions, freeze them, scrape them, laser them and kill them. 2008-06-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522703null HTML http://formularyjournal.modernmedicine.com/formulary/Basal-insulin-plus-pramlintide-at-mealtimecontrols/ArticleStandard/Article/detail/522701?ref=25 Pramlintide injection added to basal insulin at mealtime is similar to titrated rapid-acting insulin in achieving glycemic control but with a lower risk of hypoglycemia and no weight gain in patients with type 2 diabetes, said Matthew Riddle, MD, head, section of diabetes, division of endocrinology/diabetes/clinical nutrition, Oregon Health and Sciences University, Portland. 2008-06-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522701null HTML http://formularyjournal.modernmedicine.com/formulary/Gut-hormones-key-to-appetite-regulation/ArticleStandard/Article/detail/522704?ref=25 Gut hormones play a key and often overlooked role in weight loss and weight regulation. Changes in weight are determined largely by the balance between energy intake and energy expenditure, but gut hormones can affect both sides of the energy equation. 2008-06-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522704null HTML http://formularyjournal.modernmedicine.com/formulary/Surrogate-endpoints-in-drug-approval-process-exami/ArticleStandard/Article/detail/522699?ref=25 Surrogate endpoints in clinical trials (ie, hemoglobin [Hb] A1c) on which drug approvals may be based only explain narrow aspects of complex conditions. For this reason, even when using a drug as labeled, there is always a level of uncertainty over outcomes with the drug, said Saul Malozowski, MD, PhD, MPH. 2008-06-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522699null HTML http://formularyjournal.modernmedicine.com/formulary/Hyperglycemia-can-affect-NO-pathway-of-endothelial/ArticleStandard/Article/detail/522702?ref=25 Hyperglycemia is involved in the dysregulation of endothelial nitric oxide (NO) synthase, leading to endothelial dysfunction and an increased risk of vasculopathy, said Markku Laakso, MD. 2008-06-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522702null HTML http://formularyjournal.modernmedicine.com/formulary/ADA-2008-Separate-drug-classes-prevent-development/ArticleStandard/Article/detail/522697?ref=25 Pioglitazone prevented progression to type 2 diabetes in patients with impaired glucose tolerance (IGT), reported Ralph DeFronzo, MD. The effect was marked?81% fewer patients assigned to pioglitazone compared with placebo converted from IGT to type 2 diabetes in a randomized, double-blind, placebo-controlled clinical study. 2008-06-09T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522697null HTML http://formularyjournal.modernmedicine.com/formulary/Diabetic-atherosclerotic-disease-evolves-in-stages/ArticleStandard/Article/detail/522431?ref=25 Atherosclerosis and its complications develop in stages. Each of each of these stages is affected by different metabolic abnormalities, said Scott Grundy, MD, PhD, during the annual Edwin Bierman lecture. 2008-06-08T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522431null HTML http://formularyjournal.modernmedicine.com/formulary/UK-study-Subpar-glycemic-control-associated-with-p/ArticleStandard/Article/detail/522432?ref=25 British women who have poorer glycemic control before and during pregnancy have poorer outcomes and less-healthy babies. That's the take home message from CEMACH, the Confidential Enquiry into Maternal and Child Health, a year-long survey of pregnant women with type 1 and type 2 diabetes across the United Kingdom. 2008-06-08T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522432null HTML http://formularyjournal.modernmedicine.com/formulary/Novel-agents-for-glycemic-control-are-under-invest/ArticleStandard/Article/detail/522428?ref=25 Several novel classes of agents designed to treat hyperglycemia are under investigation. These agents were the subjects of a symposium here. One such novel class is the sodium glucose co-transporter (SGLT) type 2 inhibitors, which reduce glucose levels by increasing kidney excretion of glucose. The kidney plays an important role in the handling of glucose, said Robert R. Henry, MD, professor of medicine and chief of VA endocrinology and metabolism at the University of California, San Diego. SGLT-2 is expressed almost exclusively in the kidney. About 90% of glucose reabsorption by the kidney is mediated by SGLT-2 under normal circumstances. 2008-06-08T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522428null HTML http://formularyjournal.modernmedicine.com/formulary/Putting-weight-loss-into-clinical-practice/ArticleStandard/Article/detail/522427?ref=25 Translating weight loss research into clinical programs is not easy. Too many clinical protocols exist in isolation, according to Donald Williamson, PhD, Pennington Biomedical Research Center, Baton Rouge, LA. The key gap is extending methods that contribute to weight loss into programs that maintain weight loss. 2008-06-08T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522427null HTML http://formularyjournal.modernmedicine.com/formulary/ACCORD-trial-reveals-increased-risk-of-death/ArticleStandard/Article/detail/522429?ref=25 An intense glucose-lowering strategy in high-risk patients with type 2 diabetes was associated with an excess of mortality in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, the U.S. counterpart to the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation) study. 2008-06-08T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522429null HTML http://formularyjournal.modernmedicine.com/formulary/Pedal-osteolysis-can-be-biomarker-for-diabetic-dis/ArticleStandard/Article/detail/522430?ref=25 Current research suggests that pedal osteolysis, the loss of bone mineral density (BMD) in the foot, may be a useful biomarker for Charcot's arthropathy and other diabetic foot diseases. 2008-06-08T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242008/522430null HTML http://formularyjournal.modernmedicine.com/formulary/GLP-1-secretion-No-acute-affect-on-insulin/ArticleStandard/Article/detail/522388?ref=25 Take another look at the popular hypothesis that suggests type 2 diabetes has an acute effect on the secretion of GLP-1 and that lower GLP-1 secretion has an acute effect on insulin. It doesn't work that way, said Michael Nauck, MD, PhD, Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany. Decreased GLP-1 secretion is not part of the pathophysiology of type 2 diabetes. 2008-06-07T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522388null HTML http://formularyjournal.modernmedicine.com/formulary/2008+AAD+Meeting+Highlights/Type-2-diabetes-increases-fracture-risk-to-minor-d/ArticleStandard/Article/detail/522392?ref=25 The risk of fracture is probably only slightly increased in persons with type 2 diabetes, said Peter Vestergaard, MD, PhD, DrMedSc, from the Osteoporosis Clinic, Aarhus Amtssygehus, Denmark. 2008-06-07T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522392null HTML http://formularyjournal.modernmedicine.com/formulary/2008+AAD+Meeting+Highlights/Pharmacologic-options-for-painful-diabetic-neuropa/ArticleStandard/Article/detail/522390?ref=25 Good glycemic control is not sufficient to relieve painful diabetic neuropathy, necessitating investigation of other modalities to achieve analgesic efficacy. Dan Ziegler, MD, German Diabetes Clinic, German Diabetes Center, and professor of internal medicine, Leibniz Institute at the Heinrich Heine University, Düsseldorf, provided an overview of pharmacologic treatments that have been explored for painful diabetic neuropathy and the success achieved with each. 2008-06-07T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522390null HTML http://formularyjournal.modernmedicine.com/formulary/Reducing-excess-iron-levels-encourages-diabetic-wo/ArticleStandard/Article/detail/522386?ref=25 Researchers at Stanford University are reporting positive results in healing diabetic wounds with a pharmaceutical agent already approved by the FDA, but only in mice so far. 2008-06-07T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522386null HTML http://formularyjournal.modernmedicine.com/formulary/2008+AAD+Meeting+Highlights/Hepatic-steatosis-new-worry-in-type-2-diabetes/ArticleStandard/Article/detail/522387?ref=25 Clinicians and type 2 diabetes patients have a new worry: hepatic steatosis, or nonalcoholic fatty liver disease. Liver disease is a less-obvious problem than kidney disease but may have equally grave consequences. 2008-06-07T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522387null HTML http://formularyjournal.modernmedicine.com/formulary/2008+AAD+Meeting+Highlights/Human-factors-make-or-break-continuous-glucose-mon/ArticleStandard/Article/detail/522391?ref=25 Real-time continuous glucose monitoring (CGM) can significantly improve glycemic control, but it will not help all patients. "Real-time CGM will add significantly to glucose management for some people, but not for all," said Irl Hirsch, MD, University of Washington, Seattle. "Human factors make all the difference between success and failure. Some patients will never figure it out. That?s why real-time control is so challenging. 2008-06-07T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522391null HTML http://formularyjournal.modernmedicine.com/formulary/Progress-is-rapid-in-islet-cell-transplants/ArticleStandard/Article/detail/522389?ref=25 Islet cell transplants are effective in both the short- and long-term in freeing patients with diabetes from insulin injections and have proven to be safe, said Bernhard J. Hering, MD. The use of embryonic pig pancreatic precursor tissue as the source of islets appears promising and would expand the number of transplant recipients, which is currently limited by number of potential donors. 2008-06-07T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522389null HTML http://formularyjournal.modernmedicine.com/formulary/Greetings-from-the-ADA-in-San-Francisco/ArticleStandard/Article/detail/522221?ref=25 The editorial teams in the Modern Medicine Primary Care Content Group, with content from our legacy brands ? Medical Economics, Drug Topics, Geriatrics, Formulary and Contemporary OB/Gyn ? will cover key medical meetings, bringing you breaking news, the latest research findings and reports from the general sessions. 2008-06-06T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522221null HTML http://formularyjournal.modernmedicine.com/formulary/Endothelial-dysfunction-in-diabetesis-marker-cause/ArticleStandard/Article/detail/522352?ref=25 Endothelial dysfunction is both a marker for and a cause of diabetic complications. Researchers are teasing out pathways that involve oxidative stress and endothelial dysfunction, said Per-Henrik Groop, MD, PhD, Helsinki University Central Hospital, Helsinki, Finland. The challenge is in finding drugs that show the same activity in vivo that they show in cell studies or animal models. 2008-06-06T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522352null HTML http://formularyjournal.modernmedicine.com/formulary/Evidence-suggests-that-treating-periodontal-diseas/ArticleStandard/Article/detail/522350?ref=25 Periodontal disease makes glycemic control more difficult in patients with type 2 diabetes, said George W. Taylor, DrPH, DMD, associate professor of dentistry, School of Dentistry and Public Health at the University of Michigan, Ann Arbor. 2008-06-06T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522350null HTML http://formularyjournal.modernmedicine.com/formulary/Exercise-trumps-fit-and-fat-in-diabetes/ArticleStandard/Article/detail/522353?ref=25 Forget the arguments over fit and fat in the development of diabetes and the resulting complications. Both fitness and fatness can be addressed by the same prescription: physical activity. 2008-06-06T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522353null HTML http://formularyjournal.modernmedicine.com/formulary/ADVANCE-Intensive-blood-glucose-control-has-renal-/ArticleStandard/Article/detail/522351?ref=25 Intensive blood glucose control in patients with type 2 diabetes resulted in a significant reduction in the risk of microvascular complications compared with standard blood glucose control. This was driven by a reduction in the occurrence of nephropathy, in the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) study. 2008-06-06T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/522351null HTML http://formularyjournal.modernmedicine.com/formulary/CME+Showcase/Reducing-Cardiovascular-Risk-in-Patients-With-Mixe/CME/Article/detail/523762?ref=25 CME/CE Activity 2008-06-05T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/cme/formulary/242008/523762null REMOTE http://formularyjournal.modernmedicine.com/formulary/Policy+News/Reformers-seek-more-comparative-effectiveness-info/ArticleStandard/Article/detail/521928?ref=25 Healthcare reform is a high-profile issue in the presidential election campaign, and drug access has become a central theme in the debate. Both Democratic and Republican candidates have rolled out healthcare reform plans that promise to cover the uninsured while also providing tax breaks and other incentives to help individuals obtain health insurance. 2008-06-05T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/521928null HTML http://formularyjournal.modernmedicine.com/formulary/Formulary-2008-Rate-Card/ArticleStandard/Article/detail/521120?ref=25 Formulary 2008 Rate Card 2008-06-03T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/521120null PDF http://formularyjournal.modernmedicine.com/formulary/Formulary-and-Managed-Healthcare-Executive-2008-Me/ArticleStandard/Article/detail/521121?ref=25 Formulary and Managed Healthcare Executive 2008 Media Kit 2008-06-03T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/521121null PDF http://formularyjournal.modernmedicine.com/formulary/ASCO+2008+Meeting+Highlights/MRI-added-to-mammography-identifies-most-ductal-co/ArticleStandard/Article/detail/520873?ref=25 Magnetic resonance imaging (MRI) is superior to mammography alone in diagnosing intraductal components of invasive breast cancer, allowing more accurate mapping before breast conservation surgery, said Simone Schrading, MD, Department of Radiology, University of Bonn, Germany. 2008-06-02T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/520873null HTML http://formularyjournal.modernmedicine.com/formulary/ASCO+2008+Meeting+Highlights/Paroxetine-ineffective-for-insomnia-treatment-in-p/ArticleStandard/Article/detail/520878?ref=25 Physicians treating cancer-related depression with paroxetine should not expect patients' insomnia to also improve, according to a study presented by Oxana G. Palesh, PhD, University of Rochester Cancer Center, NY. "We know that insomnia and depression often occur together frequently in the general population, suggesting that there may be a common mechanism," she said. 2008-06-02T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/520878null HTML http://formularyjournal.modernmedicine.com/formulary/ASCO+2008+Meeting+Highlights/Metformin-may-have-antitumor-effects/ArticleStandard/Article/detail/520877?ref=25 Metformin may represent a novel antitumor agent, say investigators from the University of Texas M.D. Anderson Cancer Center, Houston. 2008-06-02T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/520877null HTML http://formularyjournal.modernmedicine.com/formulary/ASCO+2008+Meeting+Highlights/Clinicians-too-cautious-in-use-of-chemotherapy-for/ArticleStandard/Article/detail/520875?ref=25 Advanced age should not be a barrier to initiating adjuvant chemotherapy in patients with stage III colon cancer. In an observational study, the oldest patients suffered no more adverse events when treated with adjuvant chemotherapy than did younger patients but were much less likely than their younger counterparts to actually receive adjuvant chemotherapy for their colon cancer, said Katherine L. Khan, MD, professor of medicine at the University of California, Los Angeles. 2008-06-02T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/520875null HTML http://formularyjournal.modernmedicine.com/formulary/ASCO+2008+Meeting+Highlights/Fatigue-affects-broad-range-of-activities-among-pa/ArticleStandard/Article/detail/520874?ref=25 Cancer-related fatigue significantly interferes with patients' quality of life, and some areas often affected among these patients are not normally included on standard quality-of-life assessments, said Karen M. Mustian, PhD, University of Rochester School of Medicine, NY. More randomized, controlled trials are needed to identify these areas, she said. 2008-06-02T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232008/520874null HTML